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Introduction
There is very little authentic documentation available
regarding the statistics of breast cancer in Pakistan. True
statistics are available for only one district of Karachi, that
is District South, where a Cancer Registry has been estab-
lished. Among the few medical centers that have records
regarding their pattern of malignancies, the most common
type of malignancy affecting females of Karachi is breast
cancer. In two major hospitals in Karachi 22.95% and,
20.8% of the female malignancies were that of breast can-
cer.1 The incidence of breast cancer in Karachi is estimat-
ed to be higher than any other Asian population other than
the Jews of Israel.2
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An analysis was made to evaluate the significance of
DNA ploidy in the biology and prognosis of breast
carcinoma. This was done by estimating the correla-
tion of DNA ploidy with other established prognos-
tic markers of breast cancer, namely tumor size,
tumor grade, lymph node metastasis and S-phase
fraction.  From 1995 up to year 2000 ploidy analysis
was performed on 218 consecutive cases of infiltrat-
ing breast carcinoma by flow cytometry using forma-
lin fixed paraffin embedded material. From the labo-
ratory record, data regarding other pathological vari-
ables was retrieved. No correlation could be found
between DNA ploidy and tumor grade, nor could
there be found a correlation with tumor size. For
lymph node metastasis there was a significant differ-
ence between the proportion of aneuploids and
diploids having metastasis in more than 4 lymph
nodes. However, no significant difference was found
in axillary lymph node positive and negative groups
when number of positive lymph nodes was not taken
into account. The mean value of S-phase fraction for
the aneuploids and the diploids was also insignifi-
cantly different. In conclusion DNA ploidy alone did
not add much to predict tumor behaviour in terms of
known pathologic variables. (Pathology Oncology
Research Vol 7, No 2, 125–128, 2001)
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A few classical morphological prognostic markers such
as lymph node metastasis, tumor size and tumor grade
have stood the test of time and are the key prognostic
markers of many tumors including breast cancer. In the last
20 years, however, many novel prognostic markers have
evolved to aid in the prognosis and management of the dis-
ease. These include DNA ploidy, S-phase fraction (SPF),
oncogenes, and tumor suppressor gene products. These
cellular and molecular indicators are believed to not only
aid in the prognosis but also suggest a host of new clinical
interventions which could lead to better clinical outcome.
Flow cytometry is a technique which was developed in the
80’s to analyze tissues on a cell to cell basis. It is now pos-
sible to determine whether the DNA of each cell is normal
(diploid versus nondiploid) and the fraction of cells active-
ly synthesizing DNA. The degree of departure from nor-
mal DNA content is calculated as the DNA index (DI). By
definition, a diploid tumor has a DI of 1.0. (Standard devi-
ation, SD 0.9-1.10) Inspite of numerous studies suggesting
usefulness of ploidy and SPF estimation of neoplastic
cells, ploidy and proliferative activity is yet to prove to
have a substantial role in the diagnosis and prognosis of
most tumors on regular basis. In breast cancer since the
very beginning, conflicting data has surfaced regarding its
correlation with other established prognostic parameters. It
is now becoming obvious that DNA ploidy can only possi-
bly come up as a prognostic marker if detection is carried
out in stage I and stage II. It will obviously have very little
significance in stage III and stage IV disease. 
Initially DNA ploidy was carried out with much enthu-
siasm by many pathologists, however, its significance in
the present day pathology and oncology practice is in
question. Its role in predicting survival has also become
controversial. Some studies have found significant differ-
ence in survival between patients with aneuploidy and
those with diploidy,4 with diploids having a better progno-
sis. However there are other studies which contradict these
findings.5, 6 
In addition in later studies racial differences were also
highlighted. A study carried out by Shiao et al7 in United
States reached the conclusion that DNA ploidy holds dis-
similar significance as a prognostic marker amongst
Blacks and Whites. A study carried out by Wong et al6 in
Australia and another carried out by Chen et al8 in Taiwan
revealed different and even conflicting results. Another
study9 compares whites, blacks and Asians living in the
same locality. It follows that the significance of DNA
ploidy as a prognostic variable also depends on the race of
the population under study, and hence this study was car-
ried out to evaluate the significance of this marker in our
setting where the prevalence and particularly the age
group is much different from Western data (median age at
the time of diagnosis is approximately 49 years). 
In this study, breast tumors which were brought to the
Aga Khan university pathology laboratory, Karachi, Pak-
istan, were analyzed and DNA ploidy was compared with
the other established morphological parameters which




In this study 218 consecutive cases of breast cancer were
examined from formalin fixed paraffin embedded tissue
blocks. Only those blocks were selected which on screen-
ing showed a good proportion of representative tissue.
From the laboratory record, data regarding other patholog-
ical variables was retrieved.
Sample Preparation
Three to five 25 mm thick sections were cut from rou-
tinely fixed, paraffin embedded tissue blocks for each
case. Sections were dewaxed in two changes (2x10 min-
utes) of xylene and rehydrated in 100, 90,70 and 50%
alcohol for 10 minutes each. The sections were then rinsed
in PBS x 10 minutes and incubated in 0.5% pepsin solu-
tion at pH 1.5 at 37 °C for 30 minutes. Hypodermic nee-
dles of 40 and 25 bore were then used to break up the tis-
sue. Released nuclei were then spun, washed and cyto-
preps made to check the condition of nuclei. Nuclei were
then stained with propidium iodide in isoton (250 mg/ml)
containing 1 mg/ml RNAase for 30 minutes at 4 °C before
analyzing on FACScan (Becton-Dickinson)
Flow Cytometry
Samples were analyzed on FACScan flow cytometer
using the software MODFIT, Flow cytometric data was
acquired and displayed in standard two parameter dot plots
using FL2 width and FL2 area as the axes. This allowed to
draw gates in which debris below the first Go/G1 distrib-
ution and particles with extended time in flight (presumed
doublets) were excluded from analysis using carefully
defined and standardized gating criteria. FL2 area signals
were then used to generate single parameter DNA his-
tograms. Specimens were rejected if the median half peak
coefficient of variation (CV) of the diploid peak was more
than 5. Total of 10,000 nuclei were counted in each case.
Results
The population under study were females which were
known cases of breast cancer predominantly infiltrating
ductal carcinoma (IDC) of breast. The sample size was
218. Out of 218,53 (24%) tumors showed aneuploidy and
165 (76%) were diploid. The DI was described as either
diploid, (DI less than 1.10) or else aneuploid.The distribu-
tion of DI of the 218 breast cancer specimens is given in
Figure 1. Amongst the aneuploids, 12 cases were further
classified as near diploid (DI between 1.10 and 1.30) and
7 as tetraploid (DI between 1.90 and 2.10) cases. The
mean DI for the aneuploids was 1.632 with a median value
of 1.515. In the aneuploids 62% of the cases had axiallary
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Figure 1. Distribution of DNA indices of 218 breast cancer
specimens
lymph node metastasis compared to 54% of the diploids
which showed lymph node positivity (p-value >0.05).
There was data available regarding the SPF for 178
cases from our study group. Out of these 178 cases, there
were 21 cases of aneuploidy and 157 cases of diploidy.
The overall mean value obtained for the SPF was 21.51%.
For the aneuploids the mean SPF was 24.66% with a medi-
an value of 26.48%.
For the diploids the mean value of SPF was 21.09% with
a median value of 19.6%. Among all the 178 cases, the
SPF was below 10% (low) in only 14.04% of the cases,
between 10% and 20% (intermediate) in 35.4% of the
cases, and more than 20% (high) in 50.56% of the cases.
When the mean values of the SPF for the aneuploids and
the diploids were compared, the difference was found to
be statistically insignificant with a p-value of 0.689. The
graph in Figure 2. shows the results obtained when pro-
portions of aneuploids and diploids were compared in each
of the three categories of SPF, namely low (<10%), inter-
mediate (10% to 20%) and high (>20%).
Univariate analysis of DNA ploidy was done in relation to
tumor size, histological grade and lymph node metastasis.
Size of the tumor was divided into three categories, and
coded as 1 (0-1cm), 2 (>1 – 5 cm) and 3 (>5 cm). The pro-
portions of aneuploids falling in each category were com-
pared with proportions of diploids falling in the same cat-
egories respectively. For all three groups, the p-values
were insignificant. (Table 1.)
The proportion of aneuploids and diploids for each grade
were also compared and for all the three grades, (grade I, II
and III), there was no significant difference. (Table 2.)
Regarding lymph node status, the division was no
metastasis (0), metastasis with 1–3 lymph nodes (1) and
metastasis with 4 or more lymph nodes (2). On comparing
the proportions of aneuploids and diploids falling in each
categories, no correlation was seen in the first two cate-
gories, (with no metastasis and with metastasis in 1-3
lymph nodes). However in the third category (met. in 4 or
more lymph nodes), a weak correlation was seen with a p-
value equal to 0.05. (Table 3.)
Discussion
The aim of our study was to estimate the significance of
DNA ploidy as a prognostic marker in our setting of breast
cancer patients. The study group is representative of the
population of Pakistan, not just because the samples were
collected from Karachi, a cosmopolitan city with people
from all races present in the country, but also because the
laboratory receives samples from all over Pakistan.
Our results show that the aneuploids were 24%, whereas the
diploids were 76%. This ratio is different from some studies
carried out in other parts of the world,10,15 which showed a
majority of aneuploids amongst their sample population. This
suggests that there might be a role of inter-racial diversity.
The SPF compared with DNA ploidy revealed that there
was not a very significant difference between the mean SPF
of the aneuploids and the diploids. However, the common
trend of more aneuploids with high SPF and more diploids
with low SPF was noted in our study as well. Nonetheless
this difference is very small. Since SPF is a more established
prognostic marker of breast cancer, the absence of a signifi-
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Table 1. Relationship between ploidy status and size
Size Aneuploid No.% Diploid No.% p-value
1 1 (2.1) 4 (2.7) 0.75
2 35 (72.9) 109 (71.7) 0.8711
3 12 (25.0) 39 (25.6) 0.9274
N; Aneuploids = 48; Diploids = 152
Code for size:  (1) 0–1 cm; (2) > 1 to 5 cm; (3) > 5 cm
Table 2. Relationship between ploidy status and grade
Garde Aneuploid No.% Diploid No.% p-value
I 5 (11.9) 11 (7.6) 0.579
II 28 (66.67) 93 (64.6) 0.803
III 9 (21.46) 40 (27.8) 0.411
N; Aneuploids = 42; Diploids = 144
Table 3. Relationship between ploidy status and lymph
node metastasis
Lymphnode 
Aneuploid No % Diploid No. % p-valuemetastasis
0 18 (38.3) 68 (46) 0.3575
1 10 (21.7) 42 (28.4) 0.337
2 19 (40.4) 38 (25.6) 0.053
N; Aneuploids = 47; Diploids = 148
Code: (0) No of metastasis; (1) metastasis in 1–3 lymph
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Figure 2. Ploidy distribution of breast cancer in relation to 
S-phase fraction
cant difference in the SPF of aneuploids and diploids leads
to the conclusion that both the conditions of DNA ploidy are
not indicative of prognosis as such. Many other studies how-
ever have found significant differences.5,11-16 In our popula-
tion the mean SPFobserved was quite high, (21.51%) a fea-
ture also noted in a similar study carried out in India.15
For size, no significant correlation could be determined
in our study. This is in Contradiction to a few studies,11,17-20
however many studies have reached the same conclusion
as ours as well.15,21 For grade no correlation could be seen
with DNA ploidy, similar to another study,15 but we
noticed a high proportion of tumors presenting character-
istics of grade II carcinoma in both aneuploids and
diploids. Few studies however have found a correlation
between grade and DNA ploidy.4,6,17,22
Another factor that might be brought into consideration
here is that in our setting a lot of cases are brought to the
hospital only at an advanced stage, for multiple reasons,
when lymph node metastasis is a more significant feature
than size. In coherence to this reasoning, we did establish
a correlation of DNA ploidy with lymph node metastasis
where the proportion of aneuploids which had 4 or more
lymph nodes positive were significantly higher than
diploids, like in another study.11 Many studies carried out
in other settings do not agree with us.15,19,20,21
In summary over the last several years conflicting data has
surfaced regarding the extent of significance of DNA ploidy
with breast cancer, and there could be many possible expla-
nations. Among these interracial differences could be very
important. These differences have been noticed in earlier
studies.6-9 Another feature could be that in different laborato-
ries, the methodology of sample staining and sample prepa-
ration for running the flow cytometry test could be different.
The difference in classification could also be responsible.
We conclude by suggesting a larger study which incor-
porates not only other prognostic markers that have
become available of late but also to include the measures
of survival and disease free survival. We did not include
survival in our study because flow cytometry was intro-
duced in our laboratory only five years ago and significant
survival data is not yet available of these patients. Now as
other prognostic markers are also available their signifi-
cance should be determined for our population so that it
provides a guidance whether or not to make popular a cer-
tain particularly expensive test in our setting where
besides other considerations, one of the most important
consideration is certainly the cost to the patient.
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